Our data provide direct evidence implicating that ARF1-mediated Raf1/MEK/ERK1/2 signaling is critical for prostate tumorigenesis and that genetic approaches targeting ARF1 in animal models may provide an important and novel avenue for studying tumorigenesis and developing therapeutics. This evidence concerns the gene RAF1 and urogenital neoplasm.